REFERENCES
- Martidis A, Duker J S, Greenberg P B. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002; 109: 920–927, [PUBMED], [INFOTRIEVE], [CSA]
- McCuen BW, II, Bessler M, Tano Y, Chandler D, Machemer R. The lack of intravitreally administered triamcinolone acetonide. Am J Ophthalmol. 1981; 91: 785–788, [PUBMED], [INFOTRIEVE], [CSA]
- Denis R P, Ciulla T A, Pratt L M, Anliker W. Intravitreal triamcinolone acetonide in exudative age related macular degeneration. Retina. 2000; 20: 244–250, [CROSSREF], [CSA]
- Benz M S, Murray T G, Dubovy S R, Katz R S, Eifrig C W. Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone. Arch Ophthalmol. 2003; 121: 271, [PUBMED], [INFOTRIEVE], [CSA]
- Sutter F K, Gillies M C. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol. 2003; 87: 972–974, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Roth D R, Chich J, Spirn M J, Green S N, Yarian D L, Chaudhry N A. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol. 2003; 121: 1279–1282, [PUBMED], [CROSSREF], [CSA]
- Jonas J B, Hayler J K, Sofker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2001; 131: 468–471, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Machemer R, Sigita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc. 1979; 77: 171–180, [PUBMED], [INFOTRIEVE], [CSA]
- Denis R P, Ciulla T A, Pratt L M, Anliker W. Intravitreal triamcinolone acetonide in exudative age related macular degeneration. Retina. 2000; 20: 244–250, [CROSSREF], [CSA]
- Challa J K, Gillies M C, Penfold P L, Gyory J F, Hunyor A B, Billson F A. Exudative macular degeneration and intravitreal treamcinolone: 18 month follow-up. Aust NZ J Ophthalmol. 1998; 26: 277–281, [CSA]
- Wingate R JB, Beaumont P E. Intravitreal triamcinolone and elevated intraocular pressure. Aust NZ J Ophthalmol. 1999; 27: 431–432, [CROSSREF], [CSA]
- Jonas J B, Hayler J K, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 2000; 84: 1064–1067, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Helm C J, Holland G N. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol. 1995; 120: 55–64, [PUBMED], [INFOTRIEVE], [CSA]
- Polansky J R, Fauss D J, Chen P, Chen H, Lutjen-Drecoll E, Johnson D, Kurtz R M, Ma Z D, Bloom E, Nguyen T D. Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product. Ophthalmologica. 1997; 211: 126–139, [PUBMED], [INFOTRIEVE], [CSA]
- Hida T, Chandler D, Arena J E, Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol. 1986; 101(2)190–195, [PUBMED], [CSA]
- Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol. 2001; 29: 2–6, [CROSSREF], [CSA]
- Brown W J, Buist N R, Gipson H T, Huston R K, Kennaway N G. Fatal benzyl alcohol poisoning in a neonatal intensive care unit. Lancet 1982; 1(8283)1250, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]